GlobeNewswire by notified

Resolutions passed at the Annual General Meeting

Share

Company announcement                                                                                        
Orphazyme A/S
No. 8/2023
Ole Maaløes Vej 3
DK-2200 Copenhagen N                                                                                                                                                 

www.orphazyme.com
Company Registration No. 32266355

Copenhagen, Denmark, May 17, 2023 – Orphazyme A/S (ORPHA.CO) (the “Company”), today held its Annual General Meeting, at which the Annual General Meeting:

Financial year 2022

  • Took note of the Board of Directors’ report on the Company’s activities in the past financial year;
  • Adopted the Company’s annual report for 2022
  • Adopted that the profit related to the financial year 2022 is carried forward
  • Approved the remuneration report for 2022 (advisory vote)
  • Approved the remuneration of the Board of Directors for 2023

Discharge of liability

  • Granted discharge of liability to the Board of Directors and the Executive Management in relation to the annual report for 2022

Composition of the Board of Directors

  • Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacies as members of the Board of Directors
  • Michael Hove, Jakob Bendtsen and Jakob Have were elected as new members of the Board of Directors
  • Re-elected EY Godkendt Revisionspartnerselskab as the Company’s auditor in accordance with the recommendation from the Audit Committee
  • After the Company’s Annual General Meeting was held, the Board of Directors constituted itself by appointing Michael Hove as Chairman

An overview of the qualifications and competencies of the new members of the Board of Directors is attached to this announcement.

Proposals by the Board of Directors

  • Adopted to renew the current authorization to the Board of Directors to acquire treasury shares
  • The proposal to adopt a revised remuneration policy was withdrawn

For additional information, please contact

Orphazyme A/S

Michael Hove, Chairman of the board +45 28 12 66 09

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Første uge i tilbudsperioden i Jobindex A/S10.6.2023 12:00:37 CEST | pressemeddelelse

Danielsen 2 aps - der er hovedaktionær i Jobindex A/S - har den 2. juni 2023 fremsat et frivilligt ureguleret offentligt købstilbud om at købe aktier i Jobindex A/S til en pris på 1900 kr. pr. aktie i forbindelse med ansøgning om afnotering fra First North. På tilbudsperiodens tredje og fjerde dag har Danielsen 2 aps købt 1212 og 944 aktier á 1900 kr. pr. aktie. Den første uge har Danielsen 2 aps i alt købt 4645 aktier. Tilbudsperioden fortsætter indtil den 30. juni 2023. Det forventes at Jobindex A/S derefter vil blive afnoteret og slettet fra handel på Nasdaq First North i henhold til punkt 2.6(c)(i) i Supplement D i Nasdaqs regler. Yderligere oplysninger Direktør Kaare Danielsen, telefon 20735010, email kd@jobindex.dk Certified Adviser Jakob Tolstrup Kristensen, email jakob.tolstrup@cwicf.com Vedhæftet fil Aktiehandel tilbud 2023 juni 9

PRIX FITZGERALD 2023 LAUREATE ANNOUNCED AT HÔTEL BELLES RIVES10.6.2023 01:03:24 CEST | Press release

Quentin Tarantino Accepts 12th Annual Literary Award for Cinema Speculation CAP D’ANTIBES, France, June 09, 2023 (GLOBE NEWSWIRE) -- During an unforgettable ceremony held this evening Hôtel Belles Rives in Juan-les-Pins on the French Riviera, jury members of the 2023 Prix Fitzgerald, a French literary award created in 2011 by Marianne Estène-Chauvin, President of the Francis Scott Fitzgerald Academy and owner of Belles Rives Group, announced today this year’s laureate. The long-awaited first work of nonfiction from the author of the #1 New York Times bestselling Once Upon a Time in Hollywood, Quentin Tarantino accepted the prize for Cinema Speculation, published by HarperCollins in the United States and Weidenfeld & Nicolson in the United Kingdom on November 1, 2022 and French publishing house, Flammarion on March 22, 2023. Every year in June, the Hôtel Belles Rives hosts the Prix Fitzgerald, which honors a novel or short story that reflects the elegance, spirit, and art of living embo

FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease10.6.2023 00:45:00 CEST | Press release

Peripheral and Central Nervous System Drugs Advisory Committee votedbased on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer’s disease The PDUFA action date for traditional approval of LEQEMBI has been set for July 6, 2023, with designation of priority review LEQEMBI received accelerated approval from the FDA for the treatment of early Alzheimer’s disease on January 6, 2023 TOKYO and CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai’s Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous

Travel Startup Yovivo Expands Core Team With New Staff Members9.6.2023 20:47:00 CEST | Press release

Extended stays booking site hires Karen Kochmann (Ex-Expedia) and Erik Beekman (Ex Savills) to keep up with its fast expansion ROTTERDAM, Netherlands, June 09, 2023 (GLOBE NEWSWIRE) -- Growing startup Yovivo.com today announced its latest team expansion with the addition of two key members from the travel and real estate industries. Karen Kochmann has been taken on by Yovivo in the position of Strategic Growth Manager. Formerly Expedia’s Account Manager for the Balearic Islands (where the Yovivo offices and team are located), Karen boasts over seven years of experience, a masters degree in Digital Marketing and E-commerce, and a Banking degree from Lauder Business School. “I plan to developing strategic partnerships which will help Yovivo grow and position itself as a leading brand for extended stays. With my experience in the field of tech and tourism I will be able to bring fresh ideas to both the development of the platform and the B2C and B2B approach planned. I'll also focus on cr

Nokia Corporation: Repurchase of own shares on 09.06.20239.6.2023 20:00:00 CEST | Press release

Nokia Corporation Stock Exchange Release 9 June 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 09.06.2023 Espoo, Finland – On 9 June 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL323,9103.77CEUX33,5313.77AQEU1,0683.77TQEX14,9913.77Total373,5003.77 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and e